Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)

NCT01432483 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: Denileukin diftitox (ONTAK)

Sponsor

Eisai Inc.